No price history available.
Key financial summary
Financials in IDR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | IDRm | 1,994,540 | 2,226,573 | 1,739,054 | 1,736,990 | 1,885,822 | 2,063,817 | N/A | N/A |
| Operating profit | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | IDRm | 685,510 | 562,692 | 285,782 | 259,360 | 321,673 | 366,949 | N/A | N/A |
| EPS reported | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in IDR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Operating under its OneMed brand, PT Jayamas Medica Industri Tbk specializes in the production and distribution of a diverse array of medical devices and supplies. The company's reach extends across Indonesia, Asia, the United States, South America, and Africa. Its business operations are structured into three primary segments: manufacturing, distribution, and retail. The extensive product portfolio includes a comprehensive selection of disposable and consumable medical items, such as syringes, gauze, plaster bandages, masks, medical gloves, urine bags, foley catheters, and alcoholic tissues. Additionally, it provides various antiseptic and disinfectant solutions, including povidone iodine, medical alcohol, and blood cleansing liquids like Hdsol. Diagnostic instruments and equipment form another key category, offering everything from patient monitors, vital signs monitors, and ECG readers to syringe pumps, infusion pumps, tensimeters, and oxymeters. For mobility and rehabilitation, the company supplies products like wheelchairs, crutches, and walkers. Its biotechnology and laboratory offerings encompass pregnancy tests, PCR tests, blood collection tubes, PCT tubes, and chemical reagents. Rounding out its inventory are hospital furnishings, such as patient beds, bedside cabinets, pediatric patient beds, and surgical lamps, alongside other general consumer medical products. These essential medical goods are distributed and retailed through the company's network of Medicom stores and various digital platforms. PT Jayamas Medica Industri Tbk was founded in Sidoarjo, Indonesia, in 2000 and functions as a subsidiary of Pt. Intisumber Hasilsempurna.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
PT Jayamas Medica Industri Tbk (OMED.JK)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Operating under its OneMed brand, PT Jayamas Medica Industri Tbk specializes in the production and distribution of a diverse array of medical devices and supplies. The company's reach extends across Indonesia, Asia, the United States, South America, and Africa. Its business operations are structured into three primary segments: manufacturing, distribution, and retail. The extensive product portfolio includes a comprehensive selection of disposable and consumable medical items, such as syringes, gauze, plaster bandages, masks, medical gloves, urine bags, foley catheters, and alcoholic tissues. Additionally, it provides various antiseptic and disinfectant solutions, including povidone iodine, medical alcohol, and blood cleansing liquids like Hdsol. Diagnostic instruments and equipment form another key category, offering everything from patient monitors, vital signs monitors, and ECG readers to syringe pumps, infusion pumps, tensimeters, and oxymeters. For mobility and rehabilitation, the company supplies products like wheelchairs, crutches, and walkers. Its biotechnology and laboratory offerings encompass pregnancy tests, PCR tests, blood collection tubes, PCT tubes, and chemical reagents. Rounding out its inventory are hospital furnishings, such as patient beds, bedside cabinets, pediatric patient beds, and surgical lamps, alongside other general consumer medical products. These essential medical goods are distributed and retailed through the company's network of Medicom stores and various digital platforms. PT Jayamas Medica Industri Tbk was founded in Sidoarjo, Indonesia, in 2000 and functions as a subsidiary of Pt. Intisumber Hasilsempurna.
